ITP: a historical perspective

@article{Stasi2011ITPAH,
  title={ITP: a historical perspective},
  author={Roberto Stasi and Adrian Newland},
  journal={British Journal of Haematology},
  year={2011},
  volume={153}
}
A clinical syndrome of bleeding and purpura consistent with a diagnosis of immune thrombocytopenia (ITP) was described by Werlhof long before platelets were identified as the cellular component of blood playing an essential role in primary haemostasis. Although a role for the spleen was suggested nearly a century ago, the pathophysiology of ITP has remained elusive for many decades. During this time Werlhof’s disease was renamed idiopathic thrombocytopenic purpura, from which the acronym ITP… Expand
Immune Thrombocytopenic Purpura in Review
Background: Immune thrombocytopenic purpura (ITP) characterized by high risk of bleeding, this bleeding is due to 2 main factors the first is the damage of the platelets which is mediated byExpand
Idiopathic thrombocytopenic purpura (ITP) – new era for an old disease
TLDR
An updated review of the current clinical and laboratory data is presented, as well as a detailed analysis of the available therapeutic options with their benefits and risks, and also particular associations (pregnancy, relapsed and refractory disease, emergency treatment). Expand
The Centenary of Immune Thrombocytopenia – Part 1: Revising Nomenclature and Pathogenesis
TLDR
The role of the multiple immune components involved in the autoimmunity process is examined, focusing on the more recent mechanisms, which could be new promising therapeutic targets for ITP patients. Expand
Immune thrombocytopenic purpura
TLDR
A high index of clinical suspicion is required to accurately diagnose ITP and commence the appropriate treatment including glucocorticoids to increase the chances of a favorable prognosis as described by the authors. Expand
Background of Immune Thrombocytopenia
TLDR
The diagnosis is one of exclusion, and inherited and acquired causes of thrombocytopenia should be included in the differential diagnosis. Expand
Clinical outcome and treatment pattern linked with chronic immune thrombocytopenia at a tertiary care teaching hospital
TLDR
The aim is to retrospectively analyze data regarding the factors responsible for initiating therapy and the type of therapy instituted based upon the affordability of patients and severity of bleed to help identify patients who are at increased risk of this disease. Expand
ITP- Immune Thrombocytopenia: A Case Report
TLDR
An update on the current definitions related to immune thrombocytopenia, as per recommendations of an International Working Group (IWG) on ITP is provided. Expand
The Treatment of Immune Thrombocytopenia
TLDR
Current evidence supports alternatives to splenectomy for second-line management of patients with persistently low platelet counts and bleeding and long-term follow-up data suggest both efficacy and safety for the thrombopoietin receptor agonists (TPO-RAs). Expand
Immune thrombocytopenic purpura: Historical perspective, current status, recent advances and future directions
TLDR
The history of evolution of ITP is revisited, the current recommendations for management are summarized and the recent advances and future prospects in this field are listed. Expand
Is ITP a thrombophilic disorder?
TLDR
In patients not treated with TPO‐ra, a slightly higher risk of venous thrombosis (VTE) is consistently found in ITP, but not to a rate demanding special attention in the generality of cases. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 170 REFERENCES
Fifty years of idiopathic thrombocytopenic purpura (ITP): management of refractory itp in adults
TLDR
Using ITP as a model of human autoimmune disease could logically lead to improvements in the management of more complex disorders such as multiple sclerosis, systemic lupus erythematosus (SLE) and type I diabetes mellitus. Expand
Idiopathic thrombocytopenic purpura: current concepts in pathophysiology and management.
TLDR
Two new thrombopoietic agents, AMG 531 and eltrombobopag, have been used in clinical trials to stimulate platelet production in ITP patients not responsive to standard treatments, highlighting recent advances in both fields. Expand
Historical Aspects and Present Knowledge of Idiopathic Thrombocytopenic Purpura
Today idiopathic thrombocytopenic purpura (ITP) is recognized as a bleeding disorder that occurs either as an acute post-infectious, self-limited condition preferentially in children or as aExpand
Development of romiplostim for the treatment of patients with chronic immune thrombocytopenia: from bench to bedside
TLDR
In clinical trials, romiplostim was effective in ameliorating thrombocytopenia in patients with chronic ITP, was well tolerated and did not elicit cross‐reacting antibodies. Expand
The history of idiopathic thrombocytopenic purpura (ITP).
TLDR
The latter half of the 20th century has focused on the autoimmune components of ITP, attempting to develop diagnostic tests, apply new therapies, and elucidate the immune dysregulation associated with, and underlying, the disorder. Expand
Emerging drugs for idiopathic thrombocytopenic purpura in adults.
TLDR
Advances in the understanding of critical pathways involved in development of ITP have led to considerable progress in therapeutic strategies for ITP, and further research will ultimately determine the appropriate place of these approaches in ITP management. Expand
Primary thrombocytopenic purpura and acquired hemolytic anemia; evidence for a common etiology.
TLDR
Reports of transitory thrombocytopenia in infants of women with throm bocytopenic purpura are of particular interest, since these cases suggest that an agent producing the throma is transmissible through the placenta. Expand
SIMILARITIES BETWEEN KNOWN ANTIPLATELET ANTIBODIES AND THE FACTOR RESPONSIBLE FOR THROMBOCYTOPENIA IN IDIOPATHIC PURPURA. PHYSIOLOGIC, SEROLOGIC AND ISOTOPIC STUDIES
TLDR
Direct evidence is concerns direct evidence that the ITP factor destroys autologous platelets and is most likely an antibody. Expand
THROMBOCYTOPEN: A SUBSTANCE IN THE EXTRACT FROM THE SPLEEN OF PATIENTS WITH IDIOPATHIC THROMBOCYTOPENIC PURPURA THAT REDUCES THE NUMBER OF BLOOD PLATELETS
TLDR
An extract obtained from the spleen of patients suffering from idiopathic thrombocytopenic purpura which reduces the number of platelets in the circulating blood is described more fully. Expand
Impact of chronic Immune Thrombocytopenic Purpura (ITP) on health-related quality of life: a conceptual model starting with the patient perspective
TLDR
Developing a conceptual model to describe the impact of ITP and its treatment on patients' health-related quality of life (HRQoL) will help inform the evaluation of therapeutic strategies for ITP. Expand
...
1
2
3
4
5
...